ACP
ALNY icon

Altitude Crest Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Altitude Crest Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$29.9K – 3
2024
Q1 		$29.9K Buy
+200
New +$33.4K 0.01% 29

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Altitude Crest Partners's ALNY Position: Q2 2024 in Review

Altitude Crest Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 200 shares — an estimated $29.9K sold.

Altitude Crest Partners first reported a position in ALNY in Q1 2024 and held it in 1 quarter. The position peaked at $29.9K in Q1 2024. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Altitude Crest Partners reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 200 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $29.9K.
  • Altitude Crest Partners first reported a position in Alnylam Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's Alnylam Pharmaceuticals position peaked at $29.9K in Q1 2024.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.